Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

The Effect of Tumor Characteristics, Pre-transplant Treatments and Immunosuppression on Survival After Liver Transplantation for Hepatocellular Carcinoma - a European Registry Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02995096

Enrollment

23124

Registered

2016-12-16

Start date

2016-01-31

Completion date

2019-03-31

Last updated

2019-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Brief summary

Recurrence after liver transplantation for hepatocellular carcinoma (HCC) represents an important cause of mortality for this surgical population. In addition to tumor characteristics, It has been suggested that pre-treatment and sirolimus-based immunosuppression may affect recurrence and survival. With data from the European Liver Transplant Registry (ELTR) database, the aim of this study is to investigate the impact of tumor characteristics, pre-transplant treatment and immunosuppression regimens on survival after liver transplantation for HCC.

Interventions

PROCEDUREPre-treatment

Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)

DRUGSirolimus based immunosuppression

Immunosuppression regimens containing Sirolimus

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Hepatocellular carcinoma within transplantation criteria

Exclusion criteria

* Disseminated disease

Design outcomes

Primary

Measure	Time frame
Overall survival	up to 10 year survival

Secondary

Measure	Time frame
Hepatocellular carcinoma specific survival	5 year and 10 year survival

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026